Lead Product(s) : Satoreotide Tetraxetan,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Healthcaps India
Deal Size : $26.4 million
Deal Type : Series A Financing
Details : The proceeds from the financing will enable Ariceum to further develop its lead asset and proprietary peptide derivative, 177Lu-OPS201 (satoreotide). Satoreotide is a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
August 06, 2022
Lead Product(s) : Satoreotide Tetraxetan,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Healthcaps India
Deal Size : $26.4 million
Deal Type : Series A Financing
Lead Product(s) : Satoreotide Tetraxetan,Satoreotide Trizoxetan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
December 12, 2018
Lead Product(s) : Satoreotide Tetraxetan,Satoreotide Trizoxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Satoreotide Tetraxetan,Amino Acids Mixture
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
October 30, 2015
Lead Product(s) : Satoreotide Tetraxetan,Amino Acids Mixture
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
